Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
680- EGCG,    Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
- Review, NA, NA
NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27/CDKN1B↑, P21↑,
681- EGCG,    Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models
- vitro+vivo, BC, NA
Casp3↑, Casp8↑, Casp9↑, TumAuto↑, Beclin-1/ATG6↝, ATG5↝, GlucoseCon↓, lactateProd↓, ATP↝, HK2↓, LDHA↓, Hif1a↓, GLUT1↓, TumVol↓, VEGF↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27/CDKN1B↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
4680- EGCG,    The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review
- Review, Var, NA
CSCs↓, EMT↓, TumMeta↓, RadioS↑, ChemoSen↑, BioAv↓,
4684- EGCG,    EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells
- in-vivo, NSCLC, A549
miR-485↑, CSCs↓, CD44↓,
4681- EGCG,    Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling
- in-vitro, Ovarian, ES-2
TumCP↓, Apoptosis↑, Nanog↓, SOX2↓, Fibronectin↓, CD133↓,
4682- EGCG,    Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate
- Review, Var, NA
CSCs↓, EMT↓, ChemoSen↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, TumCP↓, Apoptosis↑, p‑GSK‐3β↓, GSK‐3β↑, β-catenin/ZEB1↓, cMyc↓, XIAP↓, Bcl-2↓, survivin↓, Vim↓, Slug↓, Snail↓,
4683- EGCG,    Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vivo, Lung, A549
CSCs↓, CD133↓, CLOCK↓, Wnt↓, β-catenin/ZEB1↓, CD44↓, SOX2↓, Nanog↓, OCT4↓,
4685- EGCG,    Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines
- in-vitro, NPC, TW01 - in-vitro, NPC, TW06
CSCs↓, EMT↓, TumCMig↓, TumCI↓, OCT4↓, Snail↓, Vim↓, E-cadherin↓, HSP70/HSPA5↓, HSP90↓, AntiTum↓,
4290- EGCG,    EGCG impedes human Tau aggregation and interacts with Tau
- in-vitro, AD, NA
*tau↓, *Dose↝, *neuroP↑, *antiOx↑,
4291- EGCG,    Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro
- in-vitro, AD, NA
*tau↓, *BBB∅,
2395- EGCG,    EGCG inhibits diabetic nephrophathy through up regulation of PKM2
- Study, Diabetic, NA
*PKM2↑, *Apoptosis↓, *PGC-1α↑,
2302- EGCG,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
TumCP↓, Hif1a↓, LDHA↓, PFK↓, cardioP↑, Glycolysis↓, PKM2↓,
2309- EGCG,  Chemo,    Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HPNE - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumCG↓, eff↑, ROS↑, ECAR↓, ChemoSen↑, selectivity↑, Glycolysis↓, PFK↓, PKA↓, HK2∅, LDHA∅, PFKP↓, PKM2↓, H2O2↑, TumW↓,
2310- EGCG,    Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells
- in-vitro, lymphoma, PEL
GLUT3↑, PDHA1↓, GDH↓, ROS↑, Glycolysis↓, OXPHOS↓,
2994- EGCG,    Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy
- Review, Var, NA
BioAv↓, NF-kB↓, Casp↑, MMP9↑, Sp1/3/4↑,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2992- EGCG,    Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity
- Review, Var, NA
AP-1↓, Sp1/3/4↓, NF-kB↓, ERK↓, P-gp/ABCB1↓, HSP27↓, β-catenin/ZEB1↓, MMPs↓, TNF-α↓, IL1β↓, MMP2↓,
2562- EGCG,    Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial
- Trial, NA, NA
AntiAg↑, other↝,
2501- EGCG,    A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea
- Case Report, AML, NA
OS↑, Remission↑, eff↑, Dose↝,
2458- EGCG,  QC,    Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies
- Analysis, Nor, NA
HK2↓,
2459- EGCG,    Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis
- in-vitro, Tong, Tca8113 - in-vitro, Tong, TSCCa
EGFR↓, Akt↓, ERK↓, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
2460- EGCG,  Taur,    Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells
- in-vitro, Nor, HSC-T6
HK2↓,
2563- EGCG,    Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies
- Review, NA, NA
cardioP↑, ROS↑, AntiAg↑, eff↑, COX1↓,
2468- EGCG,    Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists
- in-vitro, Nor, NA
*AntiAg↑, *Ca+2↓,
2561- EGCG,  ASA,    Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
- ex-vivo, Nor, NA
AntiAg↑, eff↑, Half-Life↝, other∅,
5784- EGCG,    Dietary Epicatechin Promotes Survival of Obese Diabetic Mice and Drosophila melanogaster
- in-vivo, Nor, NA
*OS↑, *Inflam↓, *LDL↓, *AntiAge↑, *GSH↑, *SOD↑, *AMPKα↑, *Weight∅,
6049- EGCG,  SeNPs,    Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity
- Study, AD, PC12
*Aβ↓, *Dose↝, *BioAv↑, *ROS↓,
5931- EGCG,  BTZ,    EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism
- in-vitro, Pca, PC3
TumAuto↑, CHOP/DDIT3↓, TumCD↓, eff↓,
1975- EGCG,    Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate
- in-vitro, Cerv, HeLa
TrxR↓, Trx↓, ROS↑, Dose↑,
1974- EGCG,    Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes
- in-vitro, Nor, NA
*ROS↓, *NO↓, *MMP↑, *i-Ca+2↓, *HO-1↑, *Catalase↑, *NRF2↑, *Trx1↑, *antiOx↑, *SOD↑, *Apoptosis↓,
1976- EGCG,    Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells
- in-vitro, GBM, U87MG
ROS↑, MMP↓, Casp3↑, Cyt‑c↑, Trx1↓, Ceru↓, IL6↓, IL8↓, MCP1/CCL2↓, RANTES?, uPA↝, ROS↑,
1514- EGCG,    Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture
- in-vitro, Cerv, HeLa - in-vitro, Nor, MCF10
selectivity↑, *toxicity∅, TumCG↓, NADHdeh?, eff↑, ENOX2↓, Dose?,
1503- EGCG,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
selectivity↑, DNMT1↓, RECK↑, MMPs↓, TumCI↓, angioG↓, TumMeta↓, HATs↓, IκB↑, NF-kB↓, IL6↓, COX2/PTGS2↓, NOS2↓, ac‑H3↑, ac‑H4↑, eff↑,
1516- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
1515- EGCG,  Phen,    Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells
- in-vitro, Cerv, HeLa - in-vitro, Nor, MCF10 - in-vitro, BC, BT20
selectivity↑, ENOX2↓, NADH↑, SK↓, eff↑, aSmase↑,
1303- EGCG,    (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation
- in-vitro, EC, NA
TumCP↓, ER-α36↓, cycD1/CCND1↓, ERK↑, Jun↓, BAX↑, Bcl-2↓, cl‑Casp3↑, ROS↑, p38↑,
1332- EMD,    Induction of Apoptosis in HepaRG Cell Line by Aloe-Emodin through Generation of Reactive Oxygen Species and the Mitochondrial Pathway
- in-vivo, Nor, HepaRG
*tumCV↓, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↑, *Bax:Bcl2↑, *Casp3↑, *Casp8↑, *Casp9↑, *cl‑PARP↑, *TumCCA↑, *P21↑, *cycE/CCNE↑, *cycA1/CCNA1↓, *CDK2↓,
1327- EMD,    Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway
- in-vitro, Lung, A549
Cyt‑c↑, Casp2↑, Casp3↑, Casp9↑, ERK↓, Akt↓, ROS↑, MMP↓, Bcl-2↓, BAX↑,
1322- EMD,    The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers
- Review, Var, NA
Apoptosis↑, TumCP↓, ROS↑, TumAuto↑, EMT↓, TGF-β↓, DNAdam↑, ER Stress↑, TumCCA↑, ATP↓, NF-kB↓, CYP1A1↑, STAC2↓, JAK↓, PI3K↓, Akt↓, MAPK↓, FASN↓, HER2/EBBR2↓, ChemoSen↑, eff↑, ChemoSen↑, angioG↓, VEGF↓, MMP2↓, eNOS↓, FOXD3↑, MMP9↓, TIMP1↑,
1323- EMD,    Anticancer action of naturally occurring emodin for the controlling of cervical cancer
- Review, Cerv, NA
TumCCA↑, DNAdam↑, mTOR↓, Casp3↑, Casp8↑, Casp9↑, TGF-β↑, SMAD3↓, p‑SMAD4↓, ROS↑, MMP↓, CXCR4↓, HER2/EBBR2↓, ER Stress↓, TumAuto↑, NOTCH1↓,
1324- EMD,    Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin
- Review, Var, NA
*toxicity↑, *BioAv↓, Akt↓, ERK↓, ROS↑, MMP↓, Bcl-2↓, BAX↑, TumCCA↑,
1325- EMD,  PacT,    Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo
- vitro+vivo, Lung, A549
TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Bcl-2↓, p‑Akt↓, p‑ERK↓, ChemoSideEff∅, ChemoSen↑,
1321- EMD,    Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model
- in-vitro, CRC, LS1034 - in-vivo, NA, NA
tumCV↓, TumCCA↑, ROS↑, Ca+2↑, MMP↓, Apoptosis↑, Cyt‑c↑, Casp9↑, Bax:Bcl2↑,
1320- EMD,  SRF,    Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7 - vitro+vivo, Hepat, SK-HEP-1
SREBF2↓, Akt↓, TumCCA↑, TumCG↓, STAT3↓,
1319- EMD,    Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
- in-vitro, Thyroid, TPC-1 - in-vitro, Thyroid, IHH4
NF-kB↓, TLR4↓, TumCI↓, TumCMig↓,
1318- EMD,    Aloe-emodin Induces Apoptosis in Human Liver HL-7702 Cells through Fas Death Pathway and the Mitochondrial Pathway by Generating Reactive Oxygen Species
- in-vitro, Nor, HL7702
*TumCCA↑, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↓, *Bax:Bcl2↑, *cl‑Casp3↑, *cl‑Casp8↑, *cl‑Casp9↑, *cl‑PARP↑,
1326- EMD,    Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells
- in-vitro, Lung, A549
Apoptosis↑, ROS↑, P53↑, BAX↑, ATM↑,
1328- EMD,    Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways
- in-vitro, Tong, SCC4
TumCCA↑, P21↑, Chk2↑, CycB/CCNB1↓, cDC2↓, Apoptosis↑, Cyt‑c↑, Casp9↑, Casp3↑, ROS↑, MMP↓, Bax:Bcl2↑, ER Stress↑,
1329- EMD,    Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells
- in-vitro, Tong, SCC4
TumCCA↑, eff↓, P53↑, P21↑, p27/CDKN1B↑, cycA1/CCNA1↓, cycE/CCNE↓, TS↓, CDC25↓, AIF↑, proCasp9↓, Cyt‑c↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp9↑,

Showing Research Papers: 3501 to 3550 of 8269
Prev Page 71 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ceru↓, 1,   CYP1A1↑, 1,   ENOX2↓, 2,   H2O2↑, 1,   NADH↑, 1,   NADHdeh?, 1,   OXPHOS↓, 1,   ROS↑, 14,   Trx↓, 1,   Trx1↓, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   ATP↝, 1,   CDC25↓, 1,   MMP↓, 7,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,   ECAR↓, 1,   FASN↓, 1,   GDH↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 4,   HK2↓, 5,   HK2∅, 1,   lactateProd↓, 2,   LDHA↓, 2,   LDHA∅, 1,   PDHA1↓, 1,   PFK↓, 2,   PFKP↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 2,   SREBF2↓, 1,   TS↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 6,   p‑Akt↓, 1,   Apoptosis↑, 8,   aSmase↑, 1,   Bak↑, 1,   BAX↑, 7,   Bax:Bcl2↑, 3,   Bcl-2↓, 7,   Bcl-xL↓, 1,   Casp↑, 2,   Casp2↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp8↑, 2,   Casp9↑, 6,   proCasp9↓, 1,   Chk2↑, 1,   Cyt‑c↑, 6,   HGF/c-Met↓, 1,   MAPK↓, 2,   p27/CDKN1B↑, 3,   p38↑, 1,   SK↓, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

FOXD3↑, 1,   HER2/EBBR2↓, 2,   Sp1/3/4↓, 2,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   other↝, 1,   other∅, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 1,   ER Stress↑, 2,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↝, 1,   Beclin-1/ATG6↝, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   DNAdam↑, 2,   DNMT1↓, 1,   DNMTs↓, 1,   P53↑, 4,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 4,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD133↓, 3,   CD44↓, 3,   cDC2↓, 1,   CLOCK↓, 1,   CSCs↓, 5,   EMT↓, 4,   ERK↓, 6,   ERK↑, 1,   p‑ERK↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC1↓, 1,   IGF-1↓, 2,   Jun↓, 1,   mTOR↓, 2,   Nanog↓, 3,   NOTCH1↓, 1,   OCT4↓, 3,   PI3K↓, 2,   PTEN↑, 1,   SOX2↓, 2,   STAT3↓, 2,   TumCG↓, 4,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 3,   AP-1↓, 1,   Ca+2↑, 1,   E-cadherin↓, 1,   ER-α36↓, 1,   Fibronectin↓, 1,   Ki-67↓, 1,   miR-485↑, 1,   MMP2↓, 2,   MMP9↓, 1,   MMP9↑, 1,   MMPs↓, 3,   PKA↓, 1,   RECK↑, 1,   Slug↓, 1,   SMAD3↓, 1,   p‑SMAD4↓, 1,   Snail↓, 2,   STAC2↓, 1,   TGF-β↓, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 6,   TumMeta↓, 2,   uPA↝, 1,   Vim↓, 2,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EGFR↓, 2,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 3,   VEGF↓, 3,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 1,   GLUT3↑, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2/PTGS2↓, 1,   CXCR4↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   IκB↑, 1,   JAK↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 7,   PSA↓, 1,   RANTES?, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv∅, 1,   ChemoSen↑, 6,   Dose?, 1,   Dose↑, 1,   Dose↝, 1,   eff↓, 3,   eff↑, 8,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 2,   HER2/EBBR2↓, 2,   IL6↓, 2,   Ki-67↓, 1,   NOS2↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↓, 1,   cardioP↑, 2,   ChemoSideEff∅, 1,   OS↑, 1,   Remission↑, 1,   toxicity∅, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 204

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 3,   ROS↑, 2,   SOD↑, 2,   Trx1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 2,   MMP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDH↓, 1,   LDL↓, 1,   PKM2↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   Bax:Bcl2↑, 2,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Fas↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   cycA1/CCNA1↓, 1,   cycE/CCNE↑, 1,   P21↓, 1,   P21↑, 2,   TumCCA↑, 2,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   i-Ca+2↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

tau↓, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 2,   Dose∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   neuroP↑, 1,   OS↑, 1,   toxicity↑, 1,   toxicity∅, 1,   Weight∅, 1,  
Total Targets: 53

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page